Condition: FGFR2 Gene Fusion/Rearrangement · Other Solid Tumors, Adult · Sponsor: Elevar Therapeutics
The goal of this clinical trial is to evaluate if lirafugratinib is efficacious and safe to treat adult patients with previously treated, unresectable, locally advanced or metastatic solid tumors (excluding cholangiocarcinoma) harboring FGFR2 fusion or rearrangement. Participants will: * Take lirafugratinib regularly as instructed by their study doctor. * Visit the clinic as instructed for checkups and tests. * Keep a diary recording each time a dose of lirafugratinib is taken.
This description comes directly from the study's public registry record.
Jacki Dillingham · +1 (385) 276-3611 · jdillingham@elevartx.com
Lissa Nazal · +1 (385) 276-3621 · lnazal@elevartx.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic | Phoenix, Arizona, United States | Not Yet Recruiting |
| Mayo Clinic | Jacksonville, Florida, United States | Not Yet Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| University of Chicago Medical Center | Chicago, Illinois, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Not Yet Recruiting |
| The University of Texas M.D. Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Institut Bergonie | Bordeaux, France | Not Yet Recruiting |
| Centre Georges François Leclerc | Dijon, France | Not Yet Recruiting |
| Centre Leon Berard | Lyon, France | Not Yet Recruiting |
| Gustave Roussy Cancer Campus | Paris, France | Not Yet Recruiting |
| Seoul National University Hospital | Seoul, South Korea | Recruiting |
+ 7 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07359820